Across TCGA pan-cancer cohorts, DMAC2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DMAC2 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DMAC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DMAC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SKCM and UCEC are the cancer types where DMAC2 Mutation most reproducibly stratifies survival.